

## Engraftment Syndrome Following Autologous Stem Cell Transplantation in a Patient Receiving Nivolumab as Salvage Therapy

Esra Terzi Demirsoy, Pınar Tarkun, Ayfer Gedük, Abdullah Hacıhanefioğlu, Özgür Mehtap  
Kocaeli University Faculty of Medicine, Department of Hematology, Kocaeli, Türkiye

Esra Terzi Demirsoy, M.D., Kocaeli University Faculty of Medicine, Department of Hematology, Kocaeli, Türkiye  
[esraterzi@gmail.com](mailto:esraterzi@gmail.com)

April 29, 2025

June 11, 2025

Engraftment syndrome (ES) is a clinical entity characterized by fever, rash, diarrhea, pulmonary infiltrates, edema, weight gain, and organ dysfunction, typically occurring within 96 hours before or after neutrophil recovery following autologous hematopoietic stem cell transplantation (ASCT). While ES is more frequently observed after ASCT in patients with multiple myeloma or POEMS syndrome, its incidence remains relatively low among patients with lymphoma (1,2). The reported incidence of ES has varied considerably across studies, largely depending on the diagnostic criteria employed. ES rates have ranged from 7% to 21% based on classical definitions, whereas some studies have reported rates as high as 59% when only fever and rash were considered [1]. Maiolino et al. later proposed broader criteria—non-infectious fever plus any of rash, pulmonary infiltrates, or diarrhea—and observed an incidence of 20%, with higher risk among patients diagnosed with conditions other than Hodgkin lymphoma [2]. Recent data further highlight the variation in ES incidence across different hematologic malignancies. In a 2024 cohort, ES was diagnosed by expert consensus in 50.9% of patients with multiple myeloma compared to only 23.9% of those with lymphoma, underscoring a substantially lower risk of ES in the lymphoma population (3).

Emerging evidence suggests that the expanding use of immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 inhibitors, may alter the post-transplant immune milieu and contribute to an increased incidence of ES in patients with classical Hodgkin lymphoma (HL). Several studies have reported a notably higher incidence of ES in ICI-exposed HL patients undergoing ASCT, with rates ranging from approximately 27% to 48% across single- and multi-center cohorts (4-6). This evolving therapeutic landscape has introduced new clinical challenges, including the development of ES or ES-like inflammatory manifestations following ASCT.

We report the case of a 60-year-old man with classical Hodgkin lymphoma, refractory after three lines of chemotherapy, who achieved complete remission with nivolumab, a PD-1 inhibitor, before undergoing ASCT. ASCT was performed 15 days after the last dose of nivolumab. On post-transplant day 5, the patient developed a diffuse, completely blanchable, pink-to-red erythematous rash initially involving the face and arms, which subsequently spread to the trunk and lower extremities. The lesions coalesced into broad patches and plaques (Figure 1) and were accompanied by a high-grade fever reaching 40°C. Within 24 hours, the patient experienced a rapid weight gain of approximately 6 kg, along with generalized subcutaneous edema and ascites, without any clinical evidence of cardiac dysfunction or hypoxemia. The onset of rash and fever coincided with neutrophil engraftment (Figure 2). At the onset of fever, empirical piperacillin-tazobactam was initiated according to the institutional febrile neutropenia protocol. A posteroanterior chest radiograph revealed no evidence of pulmonary infiltrates or consolidation. Although C-reactive protein (CRP) levels were elevated, serum procalcitonin remained within normal limits, and all microbiological cultures were negative, supporting a non-infectious inflammatory etiology. Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) was also excluded based on normal liver function tests and the absence of hepatomegaly or right upper quadrant tenderness. No alternative causes, such as infection, drug reaction, or disease relapse, were identified. Given the constellation of clinical findings, engraftment syndrome was strongly suspected, and corticosteroid therapy was initiated as the primary treatment. Diuretics were co-administered for a short duration to manage fluid overload. A rapid clinical improvement was observed following corticosteroid administration, with resolution of skin lesions and generalized edema. The clinical presentation fulfilled both the Spitzer and Maiolino criteria for the diagnosis of ES (1,2). Methylprednisolone was continued for approximately 15 days, resulting in complete resolution of the patient's symptoms. He was subsequently discharged in good clinical condition.

The increasing use of ICIs, particularly anti-PD-1 agents, in HL has raised concerns regarding immune-related complications following ASCT. Several studies have demonstrated that prior ICI therapy may predispose patients to ES or engraftment-like inflammatory events. In a single-center study, patients receiving ICIs before

ASCT had significantly higher rates of late-onset non-infectious fever or hypotension requiring fluid resuscitation unaffected (7). Other analyses have confirmed the occurrence of ES with high frequency among HL patients treated with ICIs prior to ASCT, with fever, rash, pulmonary infiltrates, and diarrhea being common features (4–5,8). Although only a minority fulfilled traditional ES diagnostic criteria, non-infectious inflammatory findings were prevalent (4,5). Early administration of corticosteroids has been associated with symptom resolution and favorable outcomes (4–5,8-9). ICIs may prime an exaggerated cytokine-mediated inflammatory response during neutrophil recovery, underscoring the need for vigilant monitoring and early intervention post-ASCT. Our case underscores the importance of maintaining a high clinical suspicion for ES in ICI-exposed patients undergoing ASCT. Timely corticosteroid intervention is critical to prevent complications. As the use of ICIs becomes more widespread in HL and other hematologic malignancies, it is imperative to better understand their impact on transplant-related outcomes and immune-mediated complications such as ES.

## References

1. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation: a systematic approach to diagnosis and management. *Bone Marrow Transplant.* 2001;27:893- 898.
2. Maiolino A, Almeida A, Spector N, Costa LJ, Nucci M. Engraftment syndrome following autologous hematopoietic stem cell transplantation: an update unifying the definition and management approach. *Bone Marrow Transplant.* 2003;31:749-754.
3. Mongkolrat S, Tantiworawit A, Niprapan P, et al. Engraftment syndrome in autologous hematopoietic stem cell transplant patients: incidence, associated risk factors, features, and outcomes. *Ann Transplant.* 2024;29:e944043.
4. Keruakous A, Palmer J, Sisk A, et al. Engraftment syndrome during autologous stem cell transplant in Hodgkin lymphoma patients treated with checkpoint inhibitors: a multi-center retrospective analysis. *Blood.* 2023;142(Suppl 1):3603.
5. Dahi PB, Glass B, Herrera AF, et al. Engraftment syndrome incidence after immune checkpoint inhibitor therapy in patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation: a single institutional review. *Blood.* 2023;142(Suppl 1):7060.
6. Odetola O, Adekola K, Moreira J, Karmali R, Ma S, Carson KR, Mehta J, Winter JN, Gordon LI, Lin AY. Engraftment syndrome incidence after immune checkpoint inhibitor therapy in patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation: a single institutional review. *Blood.* 2023;142(Suppl 1):7060.
7. Allen PB, Gooding S, Timms JA, Sureda A. The impact of prior salvage treatment with immune checkpoint inhibitors on Hodgkin lymphoma patients undergoing autologous hematopoietic stem cell transplantation: a single-center experience. *Clin Lymphoma Myeloma Leuk.* 2021;21:e726-e730.
8. Boissel N, Bouabdallah R, Brice P, et al. Engraftment syndrome, an unusual complication during autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin's lymphoma patients receiving checkpoint inhibitors as salvage therapy in the pre-transplant setting. *Blood.* 2024;144(Suppl 1):6366.
9. Diefenbach CS, Hong F, David KA, et al. Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice. *Am J Hematol.* 2021;96:708-716.



